News und Analysen
Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023
Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent, Visiopharm, Proscia®
Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023
Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent, Visiopharm, Proscia®
Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu
Agilent Technologies Inc. (NYSE: A) today announced it has partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range
Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu
Agilent Technologies Inc. (NYSE: A) today announced it has partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor
Agilent Again Named One of Barron’s 100 Most Sustainable Companies
For the sixth consecutive year, Agilent Technologies (NYSE: A) is ranked among the top 20 in Barron’s list of America’s 100 Most Sustainable Companies.
The ranking is based on the performance of
Agilent Announces Acquisition of e-MSion, Early-Stage Company Behind ECD Technology that Helps Accelerate Drug Development
Agilent Technologies Inc. (NYSE: A) today announced the acquisition of e-MSion, an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell.
Humana’s Economic Impact in Florida Totals $48 Billion
An independent economic research analysis estimated that leading health and well-being company Humana Inc. (NYSE: HUM) would contribute a total of $48 billion in overall economic impact in the
Humana Healthy Horizons Recommended by Indiana Family and Social Services Administration to Serve Medicaid Beneficiaries
Leading integrated health and wellness company Humana Inc. (NYSE: HUM) has been notified by the Indiana Family and Social Services Administration (FSSA) that FSSA is recommending Humana be awarded
Agilent Announces Global Distribution Agreement with Proscia to Accelerate Data-Driven Precision Medicine
Agilent Technologies Inc. (NYSE: A) today announced a multi-year distribution agreement with Proscia® – a leader in digital pathology – to offer a comprehensive digital diagnostic pathology system
Agilent to Present at Barclays Global Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Bob McMahon will participate in a Q&A session at the Barclays Global Healthcare Conference in Miami Beach, Florida
Humana and Aledade Announce 10 Year Collaboration
Aledade, the nation’s largest network of independent primary care, and Humana Inc. (NYSE: HUM), leading health insurer and health care services company, have announced a 10-year collaboration to
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that available data is adequate
Agilent Reports First-Quarter Fiscal Year 2023 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.76 billion for the first quarter ended January 31, 2023, an increase of 5% compared to the first quarter of 2022 and up 10% on a
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceutical
Agilent Announces Bravo NGS Automated Liquid Handling Platform with On-Deck Thermal Cycler
Agilent Technologies Inc. (NYSE: A) today announced the release of an on-deck thermal cycler (ODTC) that integrates with the Agilent Bravo NGS automated liquid handling platform. The optional ODTC
Agilent Announces Cell Analysis Workflow Automation for Immuno-Oncology, Virology, and Vaccine Development Markets
Agilent Technologies Inc. (NYSE: A) today announced their xCELLigence RTCA HT (real-time cell analysis high-throughput) platform now integrates with the BioTek BioSpa 8 Automated Incubator
Agilent Announces Cash Dividend of 22.5 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 22.5 cents per share of common stock will be paid on April 26, 2023, to all shareholders of record as of the close of
Agilent Inspires at SLAS2023, Highlighting Innovative Automated Workflow Solutions
Agilent Technologies Inc. (NYSE: A) announced today that it will highlight a suite of automated laboratory workflow solutions at the SLAS2023 International Conference and Exhibition held February
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company’s Biologics License Application (BLA) for elranatamab, an
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV)
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI®
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
Pfizer Inc. (NYSE: PFE) today announced publication of results in The Lancet Neurology from the Phase 3 pivotal clinical trial of zavegepant, an investigational calcitonin gene-related peptide
Humana Foundation Announces New Strategy to Eliminate Barriers to Equitable Health and Healthcare
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced a new strategy to advance health equity by eliminating unjust and unnecessary barriers in